64 related articles for article (PubMed ID: 20460557)
1. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors.
Yeh J; Frieze D; Martins R; Carr L
Ann Pharmacother; 2010 Jun; 44(6):1010-5. PubMed ID: 20460557
[TBL] [Abstract][Full Text] [Related]
2. Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab.
Yu Z; Xu H; Feng M; Chen L
Cancer Chemother Pharmacol; 2024 Jun; 93(6):587-593. PubMed ID: 38402561
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study.
Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Sakuragi M; Uchino E; Hiragi S; Yamamoto S; Sakai K; Matsubara T; Yanagita M; Muto M
Int J Clin Oncol; 2024 Apr; 29(4):398-406. PubMed ID: 38351273
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of proteinuria monitoring practice patterns and treatment implications in patients with cancer receiving bevacizumab products.
Sturgill K; Dicke K; Zangardi M; Osborne K
J Oncol Pharm Pract; 2023 Sep; ():10781552231198779. PubMed ID: 37654248
[TBL] [Abstract][Full Text] [Related]
5. Routine proteinuria monitoring for bevacizumab in patients with gynecologic malignancies.
Lee CS; Alwan LM; Sun X; McLean KA; Urban RR
J Oncol Pharm Pract; 2016 Dec; 22(6):771-776. PubMed ID: 26447100
[TBL] [Abstract][Full Text] [Related]
6. [Nephrotoxicity of anti-angiogenesis drugs].
Grechukhina KS; Chebotareva NV; Krasnova TN
Ter Arkh; 2020 Jul; 92(6):93-98. PubMed ID: 33346501
[TBL] [Abstract][Full Text] [Related]
7. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S; Kim C; Baer L; Zhu X
J Am Soc Nephrol; 2010 Aug; 21(8):1381-9. PubMed ID: 20538785
[TBL] [Abstract][Full Text] [Related]
9. Assessment of extended urine protein monitoring frequency in patients receiving bevacizumab.
Schiffer M; Zukovic L; Hall S; Merl MY
J Oncol Pharm Pract; 2021 Jun; 27(4):902-906. PubMed ID: 32715917
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis.
Kanbayashi Y; Ishikawa T; Tabuchi Y; Sakaguchi K; Ouchi Y; Otsuji E; Takayama K; Taguchi T
Sci Rep; 2020 Feb; 10(1):2011. PubMed ID: 32029849
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
13. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Lafayette RA; McCall B; Li N; Chu L; Werner P; Das A; Glassock R
Am J Nephrol; 2014; 40(1):75-83. PubMed ID: 25059491
[TBL] [Abstract][Full Text] [Related]
14. Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Carvalho B; Lopes RG; Linhares P; Costa A; Caeiro C; Fernandes AC; Tavares N; Osório L; Vaz R
J Neurooncol; 2020 Mar; 147(1):109-116. PubMed ID: 31974803
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report.
Endo Y; Negishi K; Hirayama K; Suzuki H; Shimizu A
Medicine (Baltimore); 2019 Nov; 98(45):e17870. PubMed ID: 31702653
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis.
Hirai T; Shuji Y; Takiyama M; Hanada K; Itoh T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):195-202. PubMed ID: 31119376
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-associated glomerular microangiopathy.
Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.
Zhao T; Wang X; Xu T; Xu X; Liu Z
Oncotarget; 2017 Aug; 8(31):51492-51506. PubMed ID: 28881662
[TBL] [Abstract][Full Text] [Related]
19. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y; Nishiyama H; Shimodaira H; Takano N; Sakaida E; Matsumoto K; Nakanishi K; Sakai H; Tsukamoto S; Komine K; Yasuda Y; Kato T; Fujiwara Y; Koyama T; Kitamura H; Kuwabara T; Yonezawa A; Okumura Y; Yakushijin K; Nozawa K; Goto H; Matsubara T; Hoshino J; Yanagita M;
Int J Clin Oncol; 2023 Oct; 28(10):1315-1332. PubMed ID: 37453935
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma: new insights and challenges for a clinician scientist.
Shingarev R; Jaimes EA
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F145-F154. PubMed ID: 28381462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]